S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
Log in
NASDAQ:ARNA

Arena Pharmaceuticals Stock Forecast, Price & News

$77.79
+0.25 (+0.32 %)
(As of 10/20/2020 12:00 AM ET)
Add
Compare
Today's Range
$76.10
Now: $77.79
$78.43
50-Day Range
$63.30
MA: $73.02
$84.59
52-Week Range
$32.95
Now: $77.79
$86.58
Volume667,504 shs
Average Volume651,460 shs
Market Capitalization$4.48 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.13
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Axovant Sciences GmbH; Outpost Medicine LLC; CY Biotech Company Limited; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Read More
Arena Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARNA
CUSIP04004710
Phone858-453-7200
Employees320

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$806.43 million
Cash Flow$7.58 per share
Book Value$21.38 per share

Profitability

Net Income$397.55 million
Net Margins-5,727.22%

Miscellaneous

Market Cap$4.48 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$77.79
+0.25 (+0.32 %)
(As of 10/20/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

How has Arena Pharmaceuticals' stock price been impacted by Coronavirus?

Arena Pharmaceuticals' stock was trading at $40.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARNA shares have increased by 92.5% and is now trading at $77.79.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Arena Pharmaceuticals?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 1 sell rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arena Pharmaceuticals
.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Arena Pharmaceuticals
.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released its quarterly earnings data on Wednesday, August, 5th. The biopharmaceutical company reported ($1.61) earnings per share for the quarter, topping analysts' consensus estimates of ($2.03) by $0.42. Arena Pharmaceuticals had a negative net margin of 5,727.22% and a negative return on equity of 31.14%. During the same quarter in the prior year, the firm earned ($1.24) earnings per share.
View Arena Pharmaceuticals' earnings history
.

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Shares of Arena Pharmaceuticals reverse split on the morning of Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ARNA?

13 brokerages have issued 1 year target prices for Arena Pharmaceuticals' shares. Their forecasts range from $58.00 to $120.00. On average, they expect Arena Pharmaceuticals' share price to reach $87.42 in the next year. This suggests a possible upside of 12.4% from the stock's current price.
View analysts' price targets for Arena Pharmaceuticals
.

Who are some of Arena Pharmaceuticals' key competitors?

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Canopy Growth (CGC), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals PLC- (GWPH) and AT&T (T).

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the following people:
  • Mr. Amit D. Munshi, Pres, CEO & Director (Age 52, Pay $1.23M)
  • Mr. Vincent E. Aurentz, Exec. VP & Chief Bus. Officer (Age 52, Pay $701.81k)
  • Dr. Preston S. Klassen, Advisor (Age 51, Pay $791.36k)
  • Mr. Robert Lisicki, Exec. VP & Chief Commercial Officer (Age 53, Pay $841.77k)
  • Ms. Laurie D. Stelzer, Exec. VP & CFO (Age 52)

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.64%), Assenagon Asset Management S.A. (0.15%), Envestnet Asset Management Inc. (0.01%), Diversified Trust Co (0.01%), Nisa Investment Advisors LLC (0.00%) and Pacer Advisors Inc. (0.00%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Christopher Cabell, Jayson Donald Alexander Dallas, Kevin Robert Lind, Manmeet Singh Soni, Preston Klassen, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz.
View institutional ownership trends for Arena Pharmaceuticals
.

Which major investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Nisa Investment Advisors LLC, and Diversified Trust Co. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Amit Munshi, Christopher Cabell, Kevin Robert Lind, Manmeet Singh Soni, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova, and Vincent Aurentz.
View insider buying and selling activity for Arena Pharmaceuticals
.

Which major investors are buying Arena Pharmaceuticals stock?

ARNA stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Pacer Advisors Inc., Envestnet Asset Management Inc., Carroll Financial Associates Inc., and CWM LLC.
View insider buying and selling activity for Arena Pharmaceuticals
.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $77.79.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $4.48 billion and generates $806.43 million in revenue each year. The biopharmaceutical company earns $397.55 million in net income (profit) each year or $7.69 on an earnings per share basis. Arena Pharmaceuticals employs 320 workers across the globe.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is www.arenapharm.com.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.